Physician profile
Mark P Goodman
NPI 1477659407
$3,569.28
in general payments reported to CMS, 2019-2025
31 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $156 · 2021: $510 · 2022: $445 · 2023: $754 · 2024: $679 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $737.55 | 2019-2025 | |
| Amgen INC. | $652.94 | 2019-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $303.59 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $247.21 | 2021-2025 | |
| Novo Nordisk INC | $179.36 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $168.78 | 2022-2025 | Sapien 3 Ultra Resilia, Evoque |
| Pfizer INC. | $164.69 | 2021-2025 | |
| Almatica Pharma LLC | $135.69 | 2022-2023 | Loreev Xr |
| Glaxosmithkline, LLC. | $94.85 | 2019-2024 | Shingrix, Arexvy |
| Heartflow, INC. | $90.17 | 2023-2025 | Ffrct |
| Idorsia Pharmaceuticals US INC | $77.99 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $74.95 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.42 | 2022-2025 | Xifaxan, Relistor |
| Merck Sharp & Dohme LLC | $60.84 | 2020-2021 | |
| Amarin Pharma, INC. | $59.40 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $58.46 | 2023 | Bodyguardian |
| Biohaven Pharmaceutical Holding Company LTD. | $55.52 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $44.52 | 2021 | |
| Arbor Pharmaceuticals, INC. | $38.46 | 2019-2021 | |
| Ibsa Pharma INC. | $33.26 | 2022-2024 | Tirosint, Licart |
| Otsuka America Pharmaceutical, INC. | $27.13 | 2023 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.97 | 2019 | |
| Noven Therapeutics, LLC | $23.75 | 2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $21.41 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.45 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $20.35 | 2024 | Breztri |
| Kowa Pharmaceuticals America, INC. | $18.29 | 2023 | Livalo, Seglentis |
| Genentech USA, INC. | $17.62 | 2019 | |
| Sun Pharmaceutical Industries INC. | $13.29 | 2021 | |
| Tanabe Pharma America, INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.